Yabao Pharmaceutical Group Co., Ltd (SHA:600351)
6.86
+0.09 (1.33%)
Feb 4, 2026, 3:00 PM CST
SHA:600351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,239 | 2,652 | 2,880 | 2,681 | 2,681 | 2,556 |
Other Revenue | 34.52 | 34.52 | 29.46 | 37.45 | 83.2 | 46.85 |
| 2,273 | 2,686 | 2,910 | 2,718 | 2,764 | 2,602 | |
Revenue Growth (YoY) | -19.73% | -7.69% | 7.05% | -1.66% | 6.21% | -14.45% |
Cost of Revenue | 1,118 | 1,323 | 1,246 | 1,216 | 1,095 | 1,073 |
Gross Profit | 1,156 | 1,363 | 1,664 | 1,502 | 1,669 | 1,529 |
Selling, General & Admin | 706.08 | 913.51 | 1,228 | 1,159 | 1,296 | 1,235 |
Research & Development | 121.9 | 139.52 | 118.29 | 130.62 | 157.13 | 144.46 |
Other Operating Expenses | 38.46 | 31.39 | 31.34 | 33.98 | 33.38 | 34.31 |
Operating Expenses | 858.74 | 1,086 | 1,373 | 1,324 | 1,473 | 1,412 |
Operating Income | 296.9 | 276.84 | 291.5 | 178.07 | 196.65 | 117.42 |
Interest Expense | -1.78 | -5.35 | -12.3 | -18.77 | -22.61 | -32.61 |
Interest & Investment Income | 6.49 | 6.45 | 9.49 | 8.18 | 22.04 | 4 |
Currency Exchange Gain (Loss) | 0.05 | 0.05 | -0.03 | 0.27 | -0.13 | -0.17 |
Other Non Operating Income (Expenses) | 11.42 | 5.96 | -9.75 | -8.01 | -3.53 | -4.24 |
EBT Excluding Unusual Items | 313.07 | 283.95 | 278.91 | 159.74 | 192.42 | 84.4 |
Impairment of Goodwill | - | - | - | -48.3 | - | - |
Gain (Loss) on Sale of Investments | -2.05 | -3.04 | -5.35 | -4.17 | 1.34 | 3.34 |
Gain (Loss) on Sale of Assets | 0.14 | 0.35 | 1.12 | 0.12 | 0.15 | 2.63 |
Asset Writedown | -87.11 | -27.53 | -84.97 | -9.75 | -22.97 | -3.44 |
Other Unusual Items | 37.42 | 38.37 | 29.26 | 28.02 | 30.66 | 40.49 |
Pretax Income | 261.46 | 292.11 | 218.98 | 125.65 | 201.59 | 127.42 |
Income Tax Expense | 67.52 | 68.19 | 39.07 | 21.04 | 17.83 | 18.43 |
Earnings From Continuing Operations | 193.94 | 223.92 | 179.91 | 104.6 | 183.76 | 108.99 |
Minority Interest in Earnings | 28.91 | 18.77 | 19.67 | 0.05 | 3.33 | -1.62 |
Net Income | 222.85 | 242.69 | 199.59 | 104.66 | 187.09 | 107.37 |
Net Income to Common | 222.85 | 242.69 | 199.59 | 104.66 | 187.09 | 107.37 |
Net Income Growth | 0.97% | 21.60% | 90.71% | -44.06% | 74.25% | 672.05% |
Shares Outstanding (Basic) | 706 | 723 | 763 | 770 | 770 | 770 |
Shares Outstanding (Diluted) | 706 | 723 | 763 | 770 | 770 | 770 |
Shares Change (YoY) | -3.67% | -5.25% | -0.89% | 0.02% | -0.04% | -0.86% |
EPS (Basic) | 0.32 | 0.34 | 0.26 | 0.14 | 0.24 | 0.14 |
EPS (Diluted) | 0.32 | 0.34 | 0.26 | 0.14 | 0.24 | 0.14 |
EPS Growth | 4.82% | 28.34% | 92.42% | -44.07% | 74.32% | 678.77% |
Free Cash Flow | 500.83 | 437.03 | 397.7 | 398.23 | 342.45 | 318.09 |
Free Cash Flow Per Share | 0.71 | 0.60 | 0.52 | 0.52 | 0.45 | 0.41 |
Dividend Per Share | 0.500 | 0.300 | 0.150 | 0.050 | 0.080 | 0.050 |
Dividend Growth | 233.33% | 100.00% | 200.00% | -37.50% | 60.00% | 150.00% |
Gross Margin | 50.84% | 50.73% | 57.19% | 55.27% | 60.39% | 58.77% |
Operating Margin | 13.06% | 10.31% | 10.02% | 6.55% | 7.12% | 4.51% |
Profit Margin | 9.80% | 9.04% | 6.86% | 3.85% | 6.77% | 4.13% |
Free Cash Flow Margin | 22.03% | 16.27% | 13.67% | 14.65% | 12.39% | 12.22% |
EBITDA | 418.15 | 412.82 | 447.11 | 338.04 | 363.93 | 287.3 |
EBITDA Margin | 18.39% | 15.37% | 15.37% | 12.44% | 13.17% | 11.04% |
D&A For EBITDA | 121.25 | 135.98 | 155.61 | 159.97 | 167.27 | 169.88 |
EBIT | 296.9 | 276.84 | 291.5 | 178.07 | 196.65 | 117.42 |
EBIT Margin | 13.06% | 10.31% | 10.02% | 6.55% | 7.12% | 4.51% |
Effective Tax Rate | 25.82% | 23.34% | 17.84% | 16.75% | 8.85% | 14.46% |
Revenue as Reported | 2,273 | 2,686 | 2,910 | 2,718 | 2,764 | 2,602 |
Advertising Expenses | - | 131.24 | 119.31 | 105.5 | 100.49 | 92.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.